-+ 0.00%
-+ 0.00%
-+ 0.00%

MindMaze Therapeutics Locks In Up to CHF4 Million Investments for Platform Deployment

MT Newswires·11/17/2026 01:23:20
Listen to the news
01:23 AM EST, 11/17/2026 (MT Newswires) -- MindMaze Therapeutics (MMTX.SW) secured commitments of up to 4 million francs from long-term strategic investors to support the commercial deployment of its neurotherapeutics platform, according to a Tuesday release. The financing comprises shares and mandatory convertible notes of 0.12 franc apiece, as well as 7 million five-year warrants at 0.25 franc apiece. Subject to customary closing conditions, the Swiss neurotherapeutics company will receive 3 million francs of the commitments in November 2026 and December 2026, with the remaining 1 million francs subject to an investment option exercisable until Feb. 28, 2027. The investments will support its efforts to expand the company's customer base and expedite the growth of its revenue.